1
|
Jiang L, Qu W, Oh T, Vincent A, Mohabbat A, Mauck W, Law L, Cha S. Sex-related demographic and symptomatologic characteristics of patients with fibromyalgia. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
2
|
Branchford BR, Stalker TJ, Law L, Acevedo G, Sather S, Brzezinski C, Wilson KM, Minson K, Lee-Sherick AB, Davizon-Castillo P, Ng C, Zhang W, Neeves KB, Lentz SR, Wang X, Frye SV, Shelton Earp H, DeRyckere D, Brass LF, Graham DK, Di Paola JA. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 2018; 16:352-363. [PMID: 29045015 PMCID: PMC5858881 DOI: 10.1111/jth.13875] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2016] [Indexed: 02/06/2023]
Abstract
Essentials Signaling by Gas6 through Tyro3/Axl/Mer receptors is essential for stable platelet aggregation. UNC2025 is a small molecule inhibitor of the Mer tyrosine kinase. UNC2025 decreases platelet activation in vitro and thrombus formation in vivo. UNC2025's anti-platelet effect is synergistic with inhibition of the ADP receptor, P2Y12 . SUMMARY Background Growth arrest-specific protein 6 signals through the TAM (TYRO-3-AXL-MERTK) receptor family, mediating platelet activation and thrombus formation via activation of the aggregate-stabilizing αIIb β3 integrin. Objective To describe the antithrombotic effects mediated by UNC2025, a small-molecule MERTK tyrosine kinase inhibitor. Methods MERTK phosphorylation and downstream signaling were assessed by immunoblotting. Light transmission aggregometry, flow cytometry and microfluidic analysis were used to evaluate the impact of MERTK inhibition on platelet activation and stability of aggregates in vitro. The effects of MERTK inhibition on arterial and venous thrombosis, platelet accumulation at microvascular injury sites and tail bleeding times were determined with murine models. The effects of combined treatment with ADP-P2Y1&12 pathway antagonists and UNC2025 were also evaluated. Results and Conclusions Treatment with UNC2025 inhibited MERTK phosphorylation and downstream activation of AKT and SRC, decreased platelet activation, and protected animals from pulmonary embolism and arterial thrombosis without increasing bleeding times. The antiplatelet effect of UNC2025 was enhanced in combination with ADP-P2Y1&12 pathway antagonists, and a greater than additive effect was observed when these two agents with different mechanisms of inhibition were coadministered. TAM kinase signaling represents a potential therapeutic target, as inhibition of this axis, especially in combination with ADP-P2Y pathway antagonism, mediates decreased platelet activation, aggregate stability, and thrombus formation, with less hemorrhagic potential than current treatment strategies. The data presented here also demonstrate antithrombotic activity mediated by UNC2025, a novel translational agent, and support the development of TAM kinase inhibitors for clinical applications.
Collapse
Affiliation(s)
- B R Branchford
- Department of Pediatrics, Section of Hematology/Oncology, University of Colorado School of Medicine, Aurora, CO, USA
- University of Colorado Hemophilia and Thrombosis Center, Aurora, CO, USA
| | - T J Stalker
- Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - L Law
- Department of Pediatrics, Section of Hematology/Oncology, University of Colorado School of Medicine, Aurora, CO, USA
| | - G Acevedo
- Department of Pediatrics, Section of Hematology/Oncology, University of Colorado School of Medicine, Aurora, CO, USA
| | - S Sather
- Department of Pediatrics, Section of Hematology/Oncology, University of Colorado School of Medicine, Aurora, CO, USA
| | - C Brzezinski
- Department of Pediatrics, Section of Hematology/Oncology, University of Colorado School of Medicine, Aurora, CO, USA
| | - K M Wilson
- Carver College of Medicine, University of Iowa, Iowa City, IA, USA
| | - K Minson
- Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, GA, USA
- Department of Pediatrics, Section of Hematology/Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - A B Lee-Sherick
- Department of Pediatrics, Section of Hematology/Oncology, University of Colorado School of Medicine, Aurora, CO, USA
| | - P Davizon-Castillo
- Department of Pediatrics, Section of Hematology/Oncology, University of Colorado School of Medicine, Aurora, CO, USA
| | - C Ng
- Department of Pediatrics, Section of Hematology/Oncology, University of Colorado School of Medicine, Aurora, CO, USA
- University of Colorado Hemophilia and Thrombosis Center, Aurora, CO, USA
| | - W Zhang
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| | - K B Neeves
- Department of Chemical & Biological Engineering, Colorado School of Mines, Golden, CO, USA
| | - S R Lentz
- Carver College of Medicine, University of Iowa, Iowa City, IA, USA
| | - X Wang
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| | - S V Frye
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
- Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, USA
| | - H Shelton Earp
- Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, USA
- Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - D DeRyckere
- Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, GA, USA
- Department of Pediatrics, Section of Hematology/Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - L F Brass
- Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - D K Graham
- Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, GA, USA
- Department of Pediatrics, Section of Hematology/Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - J A Di Paola
- Department of Pediatrics, Section of Hematology/Oncology, University of Colorado School of Medicine, Aurora, CO, USA
- University of Colorado Hemophilia and Thrombosis Center, Aurora, CO, USA
- Graduate Program - Human Medical Genetics, University of Colorado School of Medicine, Aurora, CO, USA
| |
Collapse
|
3
|
Rogers JE, Bolonesi RM, Rashid A, Elsayes KM, Elbanan MG, Law L, Kaseb A, Shroff RT. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastrointest Oncol 2017; 8:347-351. [PMID: 28480073 DOI: 10.21037/jgo.2017.03.03] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Combined hepatocellular-cholangiocarcinoma (HCC-CC) has a reported incidence of less than 5% of primary hepatic malignancies. The treatment approach to this malignancy is undefined. Our objective of this case series is to provide some insight into chemotherapy and/or targeted therapy in this setting. METHODS Pathologic and radiographic review confirmed seven combined HCC-CC patients during a 5-year time frame [2009-2014]. Data points were demographics, chemotherapy and/or targeted therapy given in the first and second-line setting, localized treatment if given, first radiographic result, progression-free survival (PFS), and overall survival (OS). RESULTS Seven patients were identified. Front-line treatment showed a median PFS of 3.4 months. Total median OS was 8.3 months. Regimens given included gemcitabine alone +/- bevacizumab, gemcitabine + platinum (GP) +/- bevacizumab, and sorafenib. Front-line treatment with these regimens showed progressive disease in 71% (5 patients) on first radiographic scan with all patients who received sorafenib front-line progressing at that restaging. Disease-control (complete response + partial response + stable disease) was seen in 29% of patients (2 patients) with 1 patient receiving GP and 1 patient receiving gemcitabine + bevacizumab. Of note, 2 patients that received GP +/- bevacizumab in the second-line setting had disease control on first radiographic scan. CONCLUSIONS Our retrospective review speaks to the rarity of this malignancy and challenges that are associated with its diagnosis and treatment. GP +/- bevacizumab showed disease control in first or second-line treatment in 3 patients. Treatment with this regimen in this rare malignancy subgroup warrants further investigation.
Collapse
Affiliation(s)
- Jane E Rogers
- Pharmacy Clinical Programs, U.T. M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | - Asif Rashid
- Department of Pathology, U.T. M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Khaled M Elsayes
- Department of Diagnostic Radiology, U.T. M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Mohamed G Elbanan
- Department of Diagnostic Radiology, U.T. M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Lindsey Law
- Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Ahmed Kaseb
- Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Rachna T Shroff
- Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX 77030, USA
| |
Collapse
|
4
|
Rogers JE, Nguyen V, Nogueras-Gonzalez GM, Crane CH, Das P, Krishnan S, Law L, Javle MM, Kaseb AO, Shroff RT. Characterization of unresectable cholangiocarcinoma patients treated with or without chemoradiation. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.3_suppl.403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
403 Background: Curative treatment for cholangiocarcinoma (CC) is surgical resection. Unfortunately, most CC patients (pts) present with unresectable disease in which gemcitabine plus platinum (GEM-P) chemotherapy is the mainstay of treatment (tx). Advanced CC has a dismal prognosis with 5-year survival reported at 5-10 %. Data regarding chemoradiation (CRT) in pts with unresectable CC (uCC) remains limited. Methods: We retrospectively reviewed uCC pts from 1/1/2009 to 7/31/2013. Primary objective: to evaluate the percentage of pts treated with CRT and the median number of chemotherapy cycles given prior to CRT. Secondary objectives: response to first-line tx, progression free survival (PFS) with or without CRT, overall survival (OS) with or without CRT, and duration of CRT control. Inclusion criteria: uCC diagnosis, received tx, and had follow-up at our institution. Exclusion criteria: pts who received liver-directed therapy other than CRT, mixed histology tumors, and a history of other malignancies. Results: 114 pts were included with 62% having intrahepatic CC. Disease control (DC) (response + stable disease) with first-line tx was 75% with 71% receiving GEM-P +/- erlotinib first-line. 65% of pts received CRT with a median of 6 chemotherapy cycles given prior to CRT. DC after CRT was 62% with a median duration of radiation control of 6.4 mths. Median PFS and OS for all pts were 13.4 mths and 27.8 mths, respectively. Median PFS in the CRT group was 14.5 mths versus 11.4 mths in the no CRT group (p = 0.105). Median OS in the CRT cohort was 29.4 mths, while median OS without CRT was 22.4 mths (p = 0.005). Median OS and PFS after CRT for pts with DC on first-line tx were 32.0 months (95% CI = 24-44 mths) and 15.7 mths (95% CI =13.5-18.8 mths), respectively. Pts who progressed on first-line tx and received CRT had a median OS of 23.8 mths (95% CI = 7-30 months) and median PFS of 4.2 mths (95% CI = 2.3-9 mths). Conclusions: Our retrospective review reveals a significant improvement in median OS with CRT in uCC pts. Those with DC on first-line tx showed improvement in PFS and OS with CRT. Patient selection is key with the benefit being highest in pts with DC with first-line tx. Our results warrant further investigation of the role of CRT in uCC.
Collapse
Affiliation(s)
- Jane Elizabeth Rogers
- Department of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Van Nguyen
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Prajnan Das
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Sunil Krishnan
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Lindsey Law
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Milind M. Javle
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Ahmed Omar Kaseb
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
5
|
Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol 2014; 5:408-13. [PMID: 25436118 PMCID: PMC4226829 DOI: 10.3978/j.issn.2078-6891.2014.072] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Accepted: 07/28/2014] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND Gemcitabine plus platinum (GEM-P) combination chemotherapy is standard treatment for first-line advanced cholangiocarcinoma (aCC). GEM-P first-line therapy reports a progression-free survival (PFS) of 8 months and overall survival (OS) of 11.7 months. Treatment in the second-line setting is less clear. Five-year survival for aCC remains dismal at 5-10%. The purpose of this study was to describe the outcomes with second-line systemic treatment at our institution. METHODS This study was a single institution retrospective chart review of aCC patients who initiated second-line systemic treatment during 1/1/2009 to 12/31/2012. The primary objective was to evaluate PFS with second-line systemic treatment. Secondary objectives were OS and disease control rate. Second-line systemic regimens were classified into four treatment groups: GEM-P, gemcitabine + fluoropyrimidine (GEM-FU), other FU combination (FU-combo), and others. RESULTS Fifty-six patients were included and the majority had intrahepatic aCC. A total of 80% received first-line gemcitabine-based therapy. Second-line therapy consisted of GEM-P (19.6%), GEM-FU (28.6%), FU-combo (37.5%), and others (14.3%). Median PFS was 2.7-month (95% CI, 2.3-3.8 months) with a median OS of 13.8 months (95% CI, 12-19.3 months) and a disease control rate of 50%. No significant difference in survival was identified between the four treatment groups. CONCLUSIONS This study revealed a 2.7-month PFS, 50% disease control rate, and potential survival benefit with second-line treatment. Options for second-line systemic therapy include GEM-FU, FU-combo, GEM-P if not given in the first-line setting. Targeted therapy with erlotinib or bevacizumab could be considered in addition to chemotherapy.
Collapse
|
6
|
Abstract
Case Study Mr. D., a 55-year-old male, presented to the medical oncology service with a diagnosis of stage III adenocarcinoma of the
sigmoid colon. He presented 7 weeks post sigmoid colectomy with lymph node resection and was initiated on adjuvant
chemotherapy with CAPOX (capecitabine [Xeloda] and oxaliplatin [Eloxatin]). Standard dosing was used: oxaliplatin at 130 mg/m2
on day 1 and capecitabine at approximately 2,000 mg/m2/day (rounded to the nearest 500-mg tablet size) for 14 days on and 7
days off (1 cycle = 21 days). A capped body surface area of 2.4 m2 was used, due to the patient’s body habitus. Adverse Effects Mr. D. did not report any complications of therapy during cycle 1, days 1–7, other than grade 1 diarrhea, which was amenable
to diphenoxylate/atropine when taken. The next week, he reported significant malaise and fatigue associated with persistent
diarrhea occurring every 30 minutes for 5 days. Mr. D. was instructed to go to the emergency room for an immediate evaluation,
but he refused. Mr. D. presented to the clinic in poor condition on day 14 of cycle 1. His diarrhea had increased to grade 3 and was not
controlled with either loperamide or diphenoxylate/atropine, though he was not taking his medications as directed. He had been
instructed to take two 2-mg loperamide tablets after the first loose stool, followed by 1 tablet of diphenoxylate/atropine 2 hours
later. He could then alternate this with loperamide every 2 hours as needed, not to exceed 8 tablets of loperamide per day. Instead,
he had taken 2 tablets of loperamide after the first loose stool, but either waited 6 hours to take 1 tablet of diphenoxylate/atropine
or otherwise chose not to alternate the medications at all despite continued diarrhea, depending on the day. Mr. D.’s timing in taking his supportive medications was inconsistent, and his explanations of this timing were not exact. He also
reported persistent grade 3 nausea with vomiting for 5 days, which did not improve with ondansetron and prochlorperazine,
though he again did not take these consistently. He was advised to alternate ondansetron and prochlorperazine every 4 hours as
needed, but only took one or the other medication approximately 3 times per day. According to Mr. D., his adverse effects initially began on day 9 of cycle 1. He had lost approximately 14 kg (31 lb) during cycle
1. Clinically, he was found to have grade 2 mucositis and grade 1 hand-foot syndrome. At the time of this visit, his absolute
neutrophil count was 3,000/ìL, his hemoglobin was 14.4 g/dL, his hematocrit 42.2%, and his platelet count was 139,000/ìL. His
kidney function was within the normal range. Mr. D. refused hospitalization despite the primary team’s recommendation. He also refused to undergo stool sampling for
Clostridium difficile. He was given IV fluids along with adjustments in supportive medications, including a prescription for 10%
tincture of opium. He was instructed to use 0.6 mL every 6 hours in addition to alternating loperamide with diphenoxylate/atropine
as noted previously. He was advised to rinse his mouth with a baking soda solution for relief of his grade 1 mucositis, and
alternation of antiemetics every 4 hours was reiterated. He was to return prior to initiation of cycle 2 for further evaluation. Worsening Symptoms The next day, Mr. D.’s wife called the clinic to report that her husband’s diarrhea continued despite the use of tincture of opium
and that it was associated with hematochezia. He was also experiencing a worsening of his mucositis, with an associated swelling of
the tongue. He was instructed to present to the emergency center, which he did on day 16 of cycle 1. By then, he was found to be
febrile at 39.5°C. He was tachycardic, with a heart rate of 126, and he was experiencing significant abdominal pain associated with
the diarrhea. The mucositis was worsening, with new odynophagia. At this time, Mr. D.’s absolute neutrophil count had dropped dramatically to 160/ìL, his hemoglobin was 13.1 g/dL, his
hematocrit was 39.2%, and his platelet count was 68,000/ìL. He was admitted to the inpatient service and started on empiric
antibiotics. His blood cultures remained negative during hospitalization, but stool cultures were positive for C. difficile. His
antimicrobial regimen was deescalated to oral vancomycin once his stool volume decreased. He was treated with an institutional
compounded mouthwash of diphenhydramine, aluminum/magnesium hydroxide, and viscous lidocaine for the mucositis, which
also slowly improved. He was given a dose of growth factor. Neutropenia eventually resolved, with an absolute neutrophil count of
4,820/ìL on the day of discharge. He was discharged 26 days after initiating cycle 1, at which time his myelosuppression and
mucositis were also resolved. Throughout his course, he did not report any neurotoxicity. DPD Testing Due to his severe symptoms of neutropenia, mucositis, and diarrhea, Mr. D. was tested for dihydropyrimidine dehydrogenase
(DPD) deficiency. Testing confirmed a heterozygous IVS14+IG>A mutation. For this reason, all further adjuvant therapy was
withheld, and he was followed on clinical surveillance only.
Collapse
Affiliation(s)
- Lindsey Law
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Jane Rogers
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Cathy Eng
- University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
7
|
Abstract
371 Background: Five-year survival for advanced cholangiocarcinoma (aCC) is reported at 5-10%. For advanced, unresectable patients, gemcitabine plus platinum (GEM-P) combination chemotherapy is common practice as first-line treatment with progression free survival (PFS) of 8 months and overall survival (OS) of 11.7 months. Data regarding chemotherapy treatment after first-line progression is limited. Methods: We performed a retrospective chart review of patients with aCC from 1/1/2009 to 12/31/2012 who received second-line chemotherapy at M.D. Anderson Cancer Center (MDACC). Median PFS was the primary endpoint. Secondary objectives included disease control rate (complete response + partial response + stable disease) and OS. Inclusion criteria: aCC diagnosis, progression on first-line therapy, and reimaging studies at MDACC. Exclusion criteria: patients who received localized treatment for aCC prior to second-line therapy or consolidative chemoradiation, mixed histology tumors, and those with a history of another malignancy. Results: 56 patients were identified, with the majority having intrahepatic aCC (95%). 80% of patients received gemcitabine based first-line treatment (GEM-P +/- erlotinib, GEM monotherapy). Second-line systemic treatment included GEM-P (19.6%), GEM + fluoropyrmidine (GEM-FU) (28.6%), fluoropyrmidine combination (FU-combo) (37.5%), and other consisting of chemotherapy or biotherapy monotherapy or combination (14.3%). Total median PFS was 2.7 months (95% CI = 2.3 to 3.8). Disease control rate was 50% with a median OS of 13.8 months (95% CI = 12 to19.3). No significant difference in PFS or OS was identified between the four second line treatment groups. A higher CA 19-9 at the start of second line treatment correlated with a worse survival (p= <0.01). Conclusions: This retrospective study revealed a 50% disease control rate, median PFS of 2.7 months, and a potential for improvement in OS in patients who received second line systemic treatment. Agents that may be considered include GEM + FU, FU-combination therapy, or GEM-P if not given first line.
Collapse
Affiliation(s)
- Jane Elizabeth Rogers
- Department of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Lindsey Law
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - D. Van Nguyen
- Department of Pharmacy Clinical Programs, The University of Texas MD Anderson University, Houston, TX
| | - Wei Qiao
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Milind M. Javle
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Ahmed Omar Kaseb
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
8
|
Kim YJ, Satapathy SK, Law L, Volfson A, Friedman B, Yang S, Sung C, Siegel DS, DeVito B. Hematemesis from ruptured aberrant right hepatic artery aneurysm eroding through the duodenal wall. Endoscopy 2012; 43 Suppl 2 UCTN:E323-4. [PMID: 22020707 DOI: 10.1055/s-0030-1256736] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- Y J Kim
- Department of Internal Medicine, Hofstra North Shore-LIJ Health system at Long Island Jewish Medical Center, New York 11040, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Hanson G, Leong J, Newman H, Law ME, Litke A, Madaras R, Wilson R, Hofmann A, Law L, Little R, Paterson JM, Pordes R, Strauch K, Tarnopolsky G. Experimental test of quantum electrodynamics for the reaction e+e−→γγ at 4 GeV center-of-mass energy. ACTA ACUST UNITED AC 2007. [DOI: 10.1007/bf02727692] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Law L, Tuscano J, Wun T, Ahlberg K, Richman C. Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia. Int J Hematol 2002; 76:360-4. [PMID: 12463601 DOI: 10.1007/bf02982697] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Filgrastim (granulocyte colony-stimulating factor) has recently been reported to successfully treat patients with leukemic relapse after allogeneic peripheral stem cell transplantation (PSCT). However, the majority of the patients who responded also developed graft-versus-host disease (GVHD). Polyserositis as a manifestation of GVHD is a rare phenomenon. We report the first case of polyserositis following the use of filgrastim to treat a patient with acute myelogenous leukemia (M7), who had relapsed after an initially successful allogeneic PSCT. The polyserositis manifested with effusions and was initially controlled with high doses of steroids and pericardial stripping; however, after a quiescent period the patient eventually developed bronchiolitis obliterans with organizing pneumonia that required additional immunosuppressive therapy. We review the literature on GVHD-associated polyserositis and offer potential explanations for its pathogenesis.
Collapse
Affiliation(s)
- L Law
- Division of Hematology/Oncology, Department of Internal Medicine, University of California, Davis, California, USA
| | | | | | | | | |
Collapse
|
11
|
Hirji Z, O'Grady S, Bonham J, Mak M, Takata-Shewchuk J, Hawkins K, Gardam M, Law L, Mazzulli T, Conly J. Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population. Infect Control Hosp Epidemiol 2002; 23:604-8. [PMID: 12400891 DOI: 10.1086/501979] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To describe compliance with and the safety and prophylactic efficacy of zanamivir among patients at risk of developing influenza-related complications after exposure to both influenza A and B viruses. DESIGN Nonrandomized trial using both historical and contemporaneous controls from ward populations within the same facility. SETTING A 547-bed urban hospital providing complex continuing care and rehabiltation. PATIENTS Fifty patients on a single ward concomitantly exposed to both influenza A and B during an influenza outbreak. INTERVENTIONS All patients were screened for symptoms of influenza and nasopharyngeal swabs were sent for viral culture prior to treatment (two oral inhalations [2 x 5 mg] twice daily for 5 days) or prophylaxis (two oral inhalations [2 x 5 mg] once daily for 14 days) with zanamivir. Patient symptoms, compliance, and drug tolerance were monitored daily. Demographic data, comorbidities, vaccination status, and functional status (Katz score) were collected for all patients. RESULTS The mean age of the patients was 70.6 years (standard deviation, +/- 16.4 years). Ninety-four percent had two or more comorbidities, 71% were dependent in two or more activities of daily living, 63% had been vaccinated for influenza, and 82% had received amantadine. Zanamivir was well tolerated, with 93% of the patients completing their course. The efficacy for preventing symptomatic infection was 82% and 91% (95% confidence interval, 62% to 98%) based on historical and contemporaneous controls, respectively. CONCLUSION These data suggest that zanamivir can be used safely and effectively as a prophylactic agent in the management of influenza outbreaks in a complex continuing care population with multiple comorbidities.
Collapse
Affiliation(s)
- Z Hirji
- The Riverdale Hospital, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Hirji Z, O'Grady S, Bonham J, Mak M, Takata-Shewchuk J, Hawkins K, Gardam M, Law L, Mazzulli T, Conly J. Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing-care population. Can Commun Dis Rep 2001; 27:21-4. [PMID: 11227819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Affiliation(s)
- Z Hirji
- Department of Microbiology, Toronto Medical Laboratories and the University of Toronto
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Lara P, Law L, Reddy G, Edelman M, Doroshow J, Lau D, Lenz H, Israel V, Albain K, Jaslowski A, Longmate J, Frankel P, Gandara D. Salvage gemcitabine (GEM) in platinum-treated non-small cell lung cancer (NSCLC): A phase II California cancer consortium trial. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80187-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Law L, Lau T, Fung T, Rogers MS, Hjelm M. Maternal serum screening for Down syndrome in a teaching hospital in Hong Kong. Chin Med J (Engl) 1999; 112:754-7. [PMID: 11601289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
OBJECTIVE To study prospectively the use of maternal serum alpha-fetoprotein (AFP) and total beta-human chorionic gonadotropin (hCG) concentrations for screening of Down syndrome in Hong Kong. METHODS AFP and total beta-hCG were measured in serum samples from 1638 singleton Chinese pregnancies at 14-22 weeks of gestation, recruited over a twelve-month period. Gestational ages were determined by ultrasonographic parameters measured at the same visit as the test for all cases. The gestational-age-specific and weight-adjusted medians for serum AFP and total beta-hCG were calculated. Risk for fetal Down syndrome (FDS) was derived by mathematical modeling of the medians together with maternal age. Amniocenteses were offered to women with a calculated FDS risk of 1:270 or greater. RESULTS The gestational-age-specific and weight-adjusted medians for maternal serum AFP were similar to previous studies while that of total beta-hCG were higher. A total of 101 patients (6.1%) were classified as being high risk for FDS, including 3.4% (48/1394) of those younger than 35 years of age and 21.7% (53/244) of those who were 35 or above. There were 4 cases of Down syndrome, 1 case of Tumer syndrome and 1 of Edward syndrome. Three out of the four cases of Down syndrome were screened positive, corresponding to a detection rate of FDS of 75%. A case of Tumer syndrome was also screened positive. A case of trisomy 18 was found to have very low levels of AFP [0.262 multiple of median (MoM)] and total beta-hCG (0.115 MoM). CONCLUSIONS Maternal serum screening using double biochemical markers (AFP and total beta-hCG) in combination with gestational dating by ultrasonography is effective in the detection of fetal Down syndrome and possibly other chromosomal disorders in Chinese pregnant women.
Collapse
Affiliation(s)
- L Law
- Department of Chemical Pathology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, NT, Hong Kong, China.
| | | | | | | | | |
Collapse
|
15
|
Chillon M, Bosch A, Zabner J, Law L, Armentano D, Welsh MJ, Davidson BL. Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C. J Virol 1999; 73:2537-40. [PMID: 9971839 PMCID: PMC104501 DOI: 10.1128/jvi.73.3.2537-2540.1999] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/1998] [Accepted: 11/10/1998] [Indexed: 11/20/2022] Open
Abstract
Group C adenovirus-mediated gene transfer to central nervous system cells is inefficient. We found that wild-type group D viruses, or recombinant adenovirus type 2 (Ad2) (group C) modified to contain Ad17 (group D) fiber, were more efficient in infecting primary cultures of neurons. Together with studies on primary vascular endothelial cells and tissue culture cell lines, our results indicate that there is not a universally applicable adenovirus serotype for use as a gene transfer vector.
Collapse
Affiliation(s)
- M Chillon
- Howard Hughes Medical Institute, University of Iowa, College of Medicine, Iowa City, Iowa, USA
| | | | | | | | | | | | | |
Collapse
|
16
|
Climstein M, Law L, Bevin M, Black I. AN AUSTRALIAN ???PHASE III??? CARDIAC REHABILITATION PROGRAM: EFFECTIVENESS IN A COMMUNITY CLUB. Med Sci Sports Exerc 1998. [DOI: 10.1097/00005768-199805001-00454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Abstract
Endodontic treatment of a permanent mandibular first molar and a second molar presumably joined by cementum is presented. This case illustrates the difficulty in interpreting the vitality testing in such a situation. It also suggests possible irreversible pulp injury of a vital healthy tooth caused by extension of the inflammatory periapical pathosis of the adjacent tooth.
Collapse
Affiliation(s)
- L Law
- Department of Endodontics, New Jersey Dental School, University of Medicine and Dentistry, Newark 07103-2400, USA
| | | | | | | |
Collapse
|
18
|
Grigoriew GA, Walmsley S, Law L, Chee SL, Yang J, Keystone J, Krajden M. Evaluation of the Merifluor immunofluorescent assay for the detection of Cryptosporidium and Giardia in sodium acetate formalin-fixed stools. Diagn Microbiol Infect Dis 1994; 19:89-91. [PMID: 7805361 DOI: 10.1016/0732-8893(94)90118-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The Merifluor Cryptosporidium/Giardia direct immunofluorescent assay (MFDFA) was used for the blinded detection of Cryptosporidium and Giardia in 100 previously tested sodium acetate formalin (SAF)-preserved fecal specimens. Examination for ova and parasites by formalin-ether concentration followed by iron-hematoxylin and Kinyon staining had demonstrated Cryptosporidium (n = 32), Giardia (n = 20) and both Giardia and Cryptosporidium (n = 5). The MFDFA detected one additional specimen with Cryptosporidium and another with Giardia and was rapid, accurate, and simple to perform.
Collapse
Affiliation(s)
- G A Grigoriew
- Department of Microbiology, Toronto Hospital, Ontario, Canada
| | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Patterns of tooth replacement in the Nile crocodile Crocodylus niloticus were evaluated in the lateral radiographs of six dried skulls of 1-year-old individuals. Additionally, the ontogeny of the succession of teeth in this species was investigated in four embryos and a hatchling, which were serially sectioned. Three-dimensional, computer-generated reconstructions of these individuals suggested that there was a regular pattern of odontogenic progression. Three morphogenetic zones could be identified in each of the age classes: an incisor, a canine, and a molar region. It was thus concluded that the Nile crocodile is hetero- rather than homodont. Zahnreihen, or tooth rows, with a periodicity of one were easily identified. © 1993 Wiley-Liss, Inc.
Collapse
Affiliation(s)
- J A Kieser
- Departments of Oral Pathology, School of Dentistry, Witwatersrand University, Johannesburg 2050, South Africa
| | - C Klapsidis
- Department of General Anatomy, School of Dentistry, Witwatersrand University, Johannesburg 2050, South Africa
| | - L Law
- Department of General Anatomy, School of Dentistry, Witwatersrand University, Johannesburg 2050, South Africa
| | - M Marion
- Department of General Anatomy, School of Dentistry, Witwatersrand University, Johannesburg 2050, South Africa
| |
Collapse
|
20
|
Abstract
Secreted proteins from cultured rat Sertoli cells were assessed for effects on phytolectin-stimulated rat splenic lymphocytes. Sertoli cell proteins (SCP) suppressed DNA, RNA and protein synthesis in stimulated rat splenic lymphocytes whether added at 0, 4, 24 and 48 h after culture initiation. SCP preparations were not toxic to cells. SCP suppressive activity was heat stable but was not associated with the carbohydrate component of SCP preparations. SCP also suppressed the proliferation of lymphoid and non-lymphoid cell lines from several different animal species but did not inhibit proliferation-independent lysis of YAC-1 target cells by rat natural killer cells. These results suggest that Sertoli cells synthesize inhibitory factors that might be secreted into seminal plasma. Furthermore, our results demonstrate that one mode of action of these factors is suppression of cell proliferation.
Collapse
Affiliation(s)
- C R Wyatt
- Department of Microbiology, Washington State University, Pullman 99164-4340
| | | | | | | | | |
Collapse
|
21
|
Abstract
The fast and accurate etiological diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis is essential. The concentration of larger volumes of peritoneal fluids may yield more isolates than conventional methods. The removal of antibiotics present in the fluids as a consequence of therapy by washing or using antibiotic-removing resins increases the yield considerably. The use of anaerobic culture media is justified if fecal organisms are suspected as the cause of the infection.
Collapse
|
22
|
Abstract
The pH dependence of several functional properties of human fetal and adult hemoglobins have been studied to determine the relative stabilities of the high and low affinity (R and T) quaternary conformations of the two proteins under different conditions. Fetal aqumethemoglobin undergoes changes in sulfhydryl reactivity, absorption spectrum, and circular dichroism in the presence of insitol hexaphospahte which are consistent with a transition from the R to T quaternary state, but only at pH values below 6.8. In adult hemoglobin this transition can be induced pH values below 7.2. Even in the absence of phosphates, the ultraviolet (uv) circular dichroism spectrum of fetal aquomethemoglobin at low pH indicates the presence of some T conformation. The initial value for the second-order rate constant for combination of fetal deoxyhemoglobin with carbon monoxide is comparable to that for adult hemoglobin in the absence of organic phosphates and is not reduced by organic phosphates as much as that for the adult protein. The apparent first-order rate constant for dissociation of CO from fully liganded fetal hemoglobin, measured by replacement with NO, increases threefold in the absence of organic phosphates, and fourfold in the presence of organic phosphates, with decreasing pH; the midpoint of the pH dependent transition occurs around 6.8. A similar increase in the apparent first-order rate constant for O2 dissociation as measured by replacement with CO, can also be seen with decreasing pH. NO-hemoglobin F can be converted to the T state even when fully liganded simply by lowering the pH, as judged by uv circular dichroism, visible difference spectrum in the region of the alpha and beta bands, and a dramatic increase in the rate of NO dissociation, measured by replacement with CO in the presence of dithionite. These results are all consistent with a model for fetal hemoglobin in which the organic phosphate site may be functionally weakened by replacement of a residue involved in ionic interactions with the negatively charged phosphate groups, but in which the low affinity T conformation is intrinsically more stable than that of adllt hemoglobin. According to this model,the differences between fetal and adult hemoglobin can be accounted for primarily in terms of the relative stabilities of R and T conformations in each of the proteins with differences in the intrinsic properties of the individual conformations contributing effects of only secondary importance.
Collapse
|
23
|
|
24
|
Arnheim N, Inouye M, Law L, Laudin A. Chemical studies on the enzymatic specificity of goose egg white lysozyme. J Biol Chem 1973; 248:233-6. [PMID: 4571225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
|